FDA Plays

[colorofmoney]

Hemispherx Biopharma to Present at the Rodman Healthcare Conference
globenewswire

Press Release Source: Hemispherx Biopharma, Inc. On Thursday May 13, 2010, 8:00 am

PHILADELPHIA, May 13, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company"), today announced that the Company will participate in the Rodman & Renshaw 6th Annual Global Healthcare Conference to be held on May 16-18, 2010 at the Grosvenor House Hotel, London, UK. Dr. William A. Carter, Hemispherx's Chairman & CEO, is scheduled to present on Monday, May 17th, at 11:30 AM BST; 6:30 AM EDT.

Programs to launch Alferon(R) N Phase II clinical trials and preparation for new clinical trials of Alferon(R) LDO and Ampligen(R), both experimental therapeutics, will be described at this conference. Dr. Carter will discuss studies and activities planned for Southeast Asia, the Pacific Rim and South America. His presentation will include an update on the clinical trials for hospitalized flu patients in India which the company and Max Neeman are seeking approval to begin in June 2010, the Indian Monsoon season.

Dr. Carter will also provide an interim report on retrospective analyses of patient samples from the completed Phase III trial of Ampligen(R) in potential treatment of Chronic Fatigue Syndrome ("CFS") conducted in collaboration with the Whittemore Peterson Institute; these studies are expected to provide a new perspective on the design of a confirmatory Phase III study in this disorder. The samples are being analyzed for the presence of XMRV, a novel retrovirus, reported to be found in approximately two-thirds of CFS patients.

The presentation will be Webcast live. Listeners can access this broadcast through Hemispherx`s Website at http://www.hemispherx.net. The webcast will be available for 30 days following the presentation.

About Hemispherx Biopharma

Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx' flagship products include Alferon N Injection(R) (FDA approved for a category of sexually transmitted diseases) and the experimental therapeutics Ampligen(R) and Alferon LDO. Ampligen(R) represents experimental RNA nucleic acids being developed for globally important debilitating diseases and disorders of the immune system. Hemispherx' platform technology includes agents for potential treatment of various severely debilitating and life threatening diseases. Hemispherx has an extensive number of patents comprising its core intellectual property estate and a fully commercialized product (Alferon N Injection(R)). The Company wholly owns and exclusively operates a GMP certified manufacturing facility in the United States for commercial products. For more information please visit www.hemispherx.net.

Information contained in this news release, other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the Company (including Ampligen(R) and Alferon(R) LDO) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Clinical trials for other potential indications of the approved biologic Alferon N Injection(R) do not imply that the product will ever be specifically approved commercially for these other treatment indications. Further, the commencement of clinical trials by Max Neeman in India is its target date but cannot be guaranteed due to a variety of risk factors outside of the parties control and should be regarded only as a forward looking estimate.

Contact:

Hemispherx Biopharma, Inc.
Company/Investor Contact:
518-398-6222
[e-mail]